Media Articles Related to Zarontin (Ethosuximide)
Once-Daily Epilepsy Drug Equivalent to Twice-Daily Drug
Source: Medscape NeurologyHeadlines [2016.04.21]
A new study shows eslicarbazepine acetate is equivalent in efficacy to twice-daily carbamazepine monotherapy.
Medscape Medical News
Epilepsy Appears Not to Interfere With Conception
Source: Medscape NeurologyHeadlines [2016.04.18]
New 'myth-busting' data suggest that women with epilepsy are just as likely to get pregnant as healthy controls, if they choose to.
Medscape Medical News
Women with epilepsy just as likely to get pregnant as healthy women of childbearing age
Source: Epilepsy News From Medical News Today [2016.04.18]
Women with epilepsy are just as likely to achieve a successful pregnancy as women without the neurological disorder, according to a new study led by research teams at multiple centers, including...
One-a-Day Anti-Seizure Drug Shows Promise for People With Epilepsy
Source: MedicineNet Seizure Specialty [2016.04.15]
Title: One-a-Day Anti-Seizure Drug Shows Promise for People With Epilepsy
Category: Health News
Created: 4/14/2016 12:00:00 AM
Last Editorial Review: 4/15/2016 12:00:00 AM
Once-a-day epilepsy drug may prevent seizures as well as twice-a-day drug
Source: Epilepsy News From Medical News Today [2016.04.14]
A new study suggests that an epilepsy drug that can be taken once a day may control seizures as well as a drug that must be taken twice a day, according to a preliminary study presented at the...
Published Studies Related to Zarontin (Ethosuximide)
Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. [2010.03.04]
BACKGROUND: Childhood absence epilepsy, the most common pediatric epilepsy syndrome, is usually treated with ethosuximide, valproic acid, or lamotrigine. The most efficacious and tolerable initial empirical treatment has not been defined... CONCLUSIONS: Ethosuximide and valproic acid are more effective than lamotrigine in the treatment of childhood absence epilepsy. Ethosuximide is associated with fewer adverse attentional effects. (ClinicalTrials.gov number, NCT00088452.) 2010 Massachusetts Medical Society
Effect of intracranial administration of ethosuximide in rats with spontaneous or pentylenetetrazol-induced spike-wave discharges. [2011.07]
PURPOSE: Generalized absence seizures are characterized by bilateral spike-wave discharges (SWDs), particularly in the frontoparietal cortical region. In WAG/Rij and GAERS rats with absence epilepsy, recent evidence indicates that SWDs arise first from the lateral somatosensory cortex (LSC), that is, the cortical focus theory...
Comparison of the antiepileptogenic effects of an early long-term treatment with ethosuximide or levetiracetam in a genetic animal model of absence epilepsy. [2010.08]
PURPOSE: Epilepsy is a heterogeneous syndrome characterized by recurrent, spontaneous seizures; continuous medication is, therefore, necessary, even after the seizures have long been suppressed with antiepileptic drug (AED) treatments. The most disturbing issue is the inability of AEDs to provide a persistent cure, because these compounds generally suppress the occurrence of epileptic seizures without necessarily having antiepileptogenic properties...
Ethosuximide converts ictogenic neurons initiating absence seizures into normal neurons in a genetic model. [2009.07]
Absence epilepsy is a form of generalized epilepsy commonly seen in children. The neuronal process by which ethosuximide (ETX), a first choice anti-absence drug, prevents absence seizures is still unresolved...
Interactions of tiagabine with ethosuximide in the mouse pentylenetetrazole-induced seizure model: an isobolographic analysis for non-parallel dose-response relationship curves. [2008.11]
The aim of this study was to characterize the interaction between tiagabine (TGB) and ethosuximide (ETS), two antiepileptic drugs, in pentylenetetrazole (PTZ)-induced clonic seizures in mice using isobolographic analysis. The nature of the interaction between the drugs administered in combination was ascertained by estimating plasma and brain concentrations of ETS and TGB using fluorescence polarization immunoassay (FPIA) and high-performance liquid chromatography (HPLC)...
Reports of Suspected Zarontin (Ethosuximide) Side Effects
Drug Ineffective (3),
Poor Quality Drug Administered (3),
Mycoplasma Infection (2),
Abdominal Discomfort (2),
Stevens-Johnson Syndrome (2),
Oral Infection (2),
Toxic Epidermal Necrolysis (2), more >>